147 related articles for article (PubMed ID: 29480512)
1. [Side effects of methylphenidate in children and the young].
Espadas M; Insa I; Chamorro M; Alda-Diez JA
Rev Neurol; 2018 Mar; 66(5):157-162. PubMed ID: 29480512
[TBL] [Abstract][Full Text] [Related]
2. Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials.
Cohen SC; Mulqueen JM; Ferracioli-Oda E; Stuckelman ZD; Coughlin CG; Leckman JF; Bloch MH
J Am Acad Child Adolesc Psychiatry; 2015 Sep; 54(9):728-36. PubMed ID: 26299294
[TBL] [Abstract][Full Text] [Related]
3. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
Frölich J; Banaschewski T; Spanagel R; Döpfner M; Lehmkuhl G
Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222
[TBL] [Abstract][Full Text] [Related]
4. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Epstein T; Patsopoulos NA; Weiser M
Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders.
Pringsheim T; Steeves T
Cochrane Database Syst Rev; 2011 Apr; (4):CD007990. PubMed ID: 21491404
[TBL] [Abstract][Full Text] [Related]
6. [Methylphenidate, tics and compulsions].
Guegant G; Crochette A
Encephale; 2000; 26(2):45-7. PubMed ID: 10858915
[TBL] [Abstract][Full Text] [Related]
7. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature.
Kraemer M; Uekermann J; Wiltfang J; Kis B
Clin Neuropharmacol; 2010 Jul; 33(4):204-6. PubMed ID: 20571380
[TBL] [Abstract][Full Text] [Related]
8. Acute dyskinesia on starting methylphenidate after risperidone withdrawal.
Hollis CP; Thompson A
Pediatr Neurol; 2007 Oct; 37(4):287-8. PubMed ID: 17903675
[TBL] [Abstract][Full Text] [Related]
9. Brief psychosis induced by methylphenidate in a child with attention deficit disorder: a case report and literature review.
Martínez-Aguayo JC; Arancibia M; Meza-Concha N; Bustamante C; Pérez-Bracchiglione J; Madrid E
Medwave; 2017 Jun; 17(5):e6980. PubMed ID: 28665917
[TBL] [Abstract][Full Text] [Related]
10. [Infantile psychosis secondary to methylphenidate].
Fernández-Fernández MA; Rufo-Campos M; Mateos-Checa R; Muñoz-Cabello B; Madruga-Garrido M; Blanco-Martínez B
Rev Neurol; 2011 Apr; 52(7):446-7. PubMed ID: 21425116
[No Abstract] [Full Text] [Related]
11. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?
Killeen MR
J Child Fam Nurs; 2000; 3(1):46-8. PubMed ID: 11022478
[No Abstract] [Full Text] [Related]
12. Methylphenidate: growth retardation.
Prescrire Int; 2011 Oct; 20(120):238-9. PubMed ID: 21970086
[TBL] [Abstract][Full Text] [Related]
13. Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder.
Park SY; Kim EJ; Cheon KA
J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):633-40. PubMed ID: 26402385
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.
Lurie S; O'Quinn A
J Neuropsychiatry Clin Neurosci; 1991; 3(1):41-50. PubMed ID: 7580171
[TBL] [Abstract][Full Text] [Related]
15. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.
Groenman AP; Schweren LJ; Dietrich A; Hoekstra PJ
Expert Opin Drug Saf; 2017 Apr; 16(4):455-464. PubMed ID: 28277842
[TBL] [Abstract][Full Text] [Related]
16. Methylphenidate-related growth impairment.
Holtkamp K; Peters-Wallraf B; Wüller S; Pfäaffle R; Herpertz-Dahlmann B
J Child Adolesc Psychopharmacol; 2002; 12(1):55-61. PubMed ID: 12014596
[TBL] [Abstract][Full Text] [Related]
17. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
[TBL] [Abstract][Full Text] [Related]
18. Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.
Anderson VR; Scott LJ
Drugs; 2006; 66(8):1117-26. PubMed ID: 16789796
[TBL] [Abstract][Full Text] [Related]
19. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
Merkel RL; Kuchibhatla A
Expert Opin Drug Saf; 2009 Nov; 8(6):655-68. PubMed ID: 19785509
[TBL] [Abstract][Full Text] [Related]
20. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
